Aktiesnakken — November 2009
-
men de kan vel for fanden da ikke opfinde et svar fra Roche
-
-
-
JA! men der er jo intet svar der....
-
minor setback, delays...
-
Carol Werther, an analyst with Summer Street Research, noted that Rituxan has been used for CLL for a very long time, and getting the approv
-
approval in that indication "is not going to change drug practice."
-
She said doctors already are getting reimbursed for unapproved cancer treatments listed in national compendia set forth by groups like the N
-
like the National Comprehensive Cancer Network, or NCCN.
-
dvs. det er der GEN skal smøre for at få gang i noget offlabelsalg?
-
og lidt mere..... særlig interessant i lyset af decembers kongres..
-
Cancer drugs listed in the national compendia may still be in clinical testing but can be reimbursed by Medicare based on evidence published
-
published at meetings like the American Society of Hematology Meeting, which takes place Dec. 5-8.
-
det er da ret afgørende...hvorfor og hvordan. Kan Arzerra så blive godkendt eller kan de NETOP blive godkendt og så fjerne hele salget af
-
arzerra i CLL???
-
og hvorfor fanden er der ingen der har sagt noget.....STINKER, SOLSEN
-
der skulle stå IKKE blive godkendt
-
coller det er helt nyt for mig at der kan give reimbursment til offlabel indikationer. Så tror da f... amerikanerne kæmper en ullige kamp
-
De er netop ved at sætte mere fokus på den ullovlige marekdsførring af offlabel indikationer. Myndighederne vil have det stoppet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind